Paraneoplastic pemphigus in a patient with Chronic Lymphocytic Leukemia (CLL)

*test repeated due to value >100 units/mL serum ME-monkey esophagus, DSG-desmoglein, Abstracts patients <60 years (1.27; p1⁄40.027). Higher SIR was shown for secondary leukemia, melanoma and head and neck cancers, while a lower SIRwas found for lung, digestive tract, and bladder cancers. The development ofOCwas associatedwith shorter survival: 16.2 years for patients with OC vs. 22.9 years for patients without OC (p1⁄40.035). Factors that independently predicted development of OC were advanced age, male gender and lower platelet count. Conclusions: We confirmed in a large cohort of LTS patients with CLL that the overall incidence of OC is increased as compared to the general population. An increased risk of OC may persist indefinitely in patients with CLL, independently from their treatment status. In these patients the presence of OC represents an independent predictor of shorter survival.